Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
2877 Stock Overview
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
China Shineway Pharmaceutical Group Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$6.43 |
52 Week High | HK$9.93 |
52 Week Low | HK$5.50 |
Beta | 0.83 |
1 Month Change | 9.17% |
3 Month Change | -2.13% |
1 Year Change | -15.62% |
3 Year Change | -9.18% |
5 Year Change | -18.61% |
Change since IPO | 33.26% |
Recent News & Updates
China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
The yearly results for China Shineway Pharmaceutical Group Limited ( HKG:2877 ) were released last week, making it a...
Shareholder Returns
2877 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 3.4% | 8.4% | 2.1% |
1Y | -15.6% | -43.3% | -23.3% |
Return vs Industry: 2877 exceeded the Hong Kong Pharmaceuticals industry which returned -43.3% over the past year.
Return vs Market: 2877 exceeded the Hong Kong Market which returned -23.3% over the past year.
Price Volatility
2877 volatility | |
---|---|
2877 Average Weekly Movement | 5.4% |
Pharmaceuticals Industry Average Movement | 6.1% |
Market Average Movement | 7.0% |
10% most volatile stocks in HK Market | 13.8% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 2877 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 2877's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 3,674 | n/a | https://www.shineway.com |
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products.
China Shineway Pharmaceutical Group Fundamentals Summary
2877 fundamental statistics | |
---|---|
Market Cap | CN¥4.14b |
Earnings (TTM) | CN¥556.67m |
Revenue (TTM) | CN¥3.22b |
7.4x
P/E Ratio1.3x
P/S RatioIs 2877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2877 income statement (TTM) | |
---|---|
Revenue | CN¥3.22b |
Cost of Revenue | CN¥813.21m |
Gross Profit | CN¥2.41b |
Other Expenses | CN¥1.85b |
Earnings | CN¥556.67m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0.74 |
Gross Margin | 74.77% |
Net Profit Margin | 17.27% |
Debt/Equity Ratio | 0% |
How did 2877 perform over the long term?
See historical performance and comparisonDividends
7.1%
Current Dividend Yield53%
Payout RatioValuation
Is 2877 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2877?
Other financial metrics that can be useful for relative valuation.
What is 2877's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | CN¥4.14b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does 2877's PE Ratio compare to its peers?
2877 PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7.7x |
Price-To-Earnings vs Peers: 2877 is good value based on its Price-To-Earnings Ratio (7.4x) compared to the peer average (7.7x).
Price to Earnings Ratio vs Industry
How does 2877's PE Ratio compare vs other companies in the Hong Kong Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 2877 is good value based on its Price-To-Earnings Ratio (7.4x) compared to the Hong Kong Pharmaceuticals industry average (9.6x)
Price to Earnings Ratio vs Fair Ratio
What is 2877's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 7.4x |
Fair PE Ratio | 11.8x |
Price-To-Earnings vs Fair Ratio: 2877 is good value based on its Price-To-Earnings Ratio (7.4x) compared to the estimated Fair Price-To-Earnings Ratio (11.8x).
Share Price vs Fair Value
What is the Fair Price of 2877 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2877 (HK$6.43) is trading below our estimate of fair value (HK$27.57)
Significantly Below Fair Value: 2877 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 2877 is good value based on its PEG Ratio (0.7x)
Discover undervalued companies
Future Growth
How is China Shineway Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
10.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2877's forecast earnings growth (10.3% per year) is above the savings rate (1.5%).
Earnings vs Market: 2877's earnings (10.3% per year) are forecast to grow slower than the Hong Kong market (17% per year).
High Growth Earnings: 2877's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2877's revenue (13.1% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).
High Growth Revenue: 2877's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2877's Return on Equity is forecast to be low in 3 years time (11.9%).
Discover growth companies
Past Performance
How has China Shineway Pharmaceutical Group performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-5.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2877 has high quality earnings.
Growing Profit Margin: 2877's current net profit margins (17.3%) are higher than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: 2877's earnings have declined by 5.6% per year over the past 5 years.
Accelerating Growth: 2877's earnings growth over the past year (88.7%) exceeds its 5-year average (-5.6% per year).
Earnings vs Industry: 2877 earnings growth over the past year (88.7%) exceeded the Pharmaceuticals industry 16.1%.
Return on Equity
High ROE: 2877's Return on Equity (9.4%) is considered low.
Discover strong past performing companies
Financial Health
How is China Shineway Pharmaceutical Group's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 2877's short term assets (CN¥5.7B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 2877's short term assets (CN¥5.7B) exceed its long term liabilities (CN¥204.1M).
Debt to Equity History and Analysis
Debt Level: 2877 is debt free.
Reducing Debt: 2877 had no debt 5 years ago.
Debt Coverage: 2877 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 2877 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is China Shineway Pharmaceutical Group current dividend yield, its reliability and sustainability?
Dividend Score
3/6Dividend Score 3/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
7.12%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2877's dividend (7.12%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.74%).
High Dividend: 2877's dividend (7.12%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.89%).
Stability and Growth of Payments
Stable Dividend: 2877's dividend payments have been volatile in the past 10 years.
Growing Dividend: 2877's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (52.9%), 2877's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (48.3%), 2877's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
11.7yrs
Average board tenure
CEO
China Shineway Pharmaceutical Group has no CEO, or we have no data on them.
Board Members
Experienced Board: 2877's board of directors are seasoned and experienced ( 11.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
China Shineway Pharmaceutical Group Limited's employee growth, exchange listings and data sources
Key Information
- Name: China Shineway Pharmaceutical Group Limited
- Ticker: 2877
- Exchange: SEHK
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$4.857b
- Shares outstanding: 755.40m
- Website: https://www.shineway.com
Number of Employees
Location
- China Shineway Pharmaceutical Group Limited
- No. 168 Shiluan Street
- Luancheng District
- Shijiazhuang
- Hebei Province
- 51430
- China
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.